Abstract #1159

Tracking the evolution of individual prostate cancer metastases in patients under the selective pressure of Radium-223 treatment using whole-body radiomics.

Matthew D Blackledge^1,2, Dow Mu Koh^1,2, David J Collins^1,2, Matthew R Orton^1,2, Erica Scurr², Julie Hughes², Chris Parker^1,3, Martin O Leach^1,2, and Nina Tunariu^1,2

¹Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, ²MRI Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom, ³Urology Department, The Royal Marsden NHS Foundation Trust, London, United Kingdom

Whole-Body Diffusion-Weighted-MRI is emerging as an imaging response biomarker in metastatic bone disease. Tumour heterogeneity resulting in differential response to therapy is a well-recognized phenomenon. We propose that calculating radiomic features from the apparent diffusion coefficients within individual lesions can identify differential response patterns in whole-body bone disease. Robust statistical assessment of radiomic features based on repeatability assessment aids identification of significant changes.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.